Pertuzumab biosimilar (CinnaGen)

帕妥珠单抗生物类似药（CinnaGen）

Report date: 2022/04/29 16:25:03

Base Information

Drug NamePertuzumab biosimilar (CinnaGen)
Drug Alias NameAnti-2C4 monoclonal antibody培妥珠单抗Pertuzumabum珀妥珠单抗帕妥株单抗
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIran
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCinnagen
China Registration ClassN/A

Develop Information

Active CompaniesCinnagen
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG